Blog

ニュース

404

ファーマインテリジェンス・アワード・ジャパン2022受賞記念ウェビナー『低分子によるPPI阻害:新たな創薬パラダイム』のお知らせ

ファーマインテリジェンス・アワード・ジャパン2022受賞記念ウェビナー『低分子によるPPI阻害:新たな創薬パラダイム』のお知らせ

PRISM BioLab’s proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm. In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup,...

株式会社PRISM BioLab、エーザイ株式会社より資金調達

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...

E7386, a selective inhibitor of the interaction between β-catenin and CBP, exerts antitumor activity in tumor models with activated canonical wnt signaling

Cancer Research, 81(4), 1052-1062 (2021)
Yamada, Kazuhiko; Hori, Yusaku; Inoue, Satoshi; Yamamoto, Yuji; Iso, Kentaro; Kamiyama, Hiroshi; Yamaguchi, Atsumi; Kimura, Takayuki; Uesugi, Mai; Ito, Junichi; Matsuki, Masahiro; Nakamoto, Kazutaka; Harada, Hitoshi; Yoneda, Naoki; Takemura, Atsushi; Kushida, Ikuo; Wakayama, Naomi; Kubara, Kenji; Kato, Yu; Semba, Taro; Yokoi, Akira; Matsukura, Masayuki; Odagami, Takenao; Iwata, Masao; Tsuruoka, Akihiko; Uenaka, Toshimitsu; Matsui, Junji; Matsushima, Tomohiro; Nomoto, Kenichi; Kouji, Hiroyuki; Owa, Takashi; Funahashi, Yasuhiro; Ozawa, Yoichi

Scroll to top
jaJapanese